BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28772207)

  • 1. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).
    Aggoune D; Sorel N; Bonnet ML; Goujon JM; Tarte K; Hérault O; Domenech J; Réa D; Legros L; Johnson-Ansa H; Rousselot P; Cayssials E; Guerci-Bresler A; Bennaceur-Griscelli A; Chomel JC; Turhan AG
    Leuk Res; 2017 Sep; 60():94-102. PubMed ID: 28772207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs.
    Benjamin ESB; Vinod E; Illangeswaran RSS; Rajamani BM; Vidhyadharan RT; Bagchi A; Maity A; Mohan A; Parasuraman G; Amirtham SM; Abraham A; Velayudhan SR; Balasubramanian P
    Cell Signal; 2024 Apr; 116():111067. PubMed ID: 38281615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro.
    Fu FF; Zhu XJ; Wang HX; Zhang LM; Yuan GL; Chen ZC; Li QB
    Acta Pharmacol Sin; 2017 Nov; 38(11):1475-1485. PubMed ID: 28836580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Isolation and identification of chronic myelogenous leukemia bone marrow mesenchymal stem cells and their functional characteristics].
    Zhao ZG; Tang XQ; Li J; Shi MX; Zou P
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2054-7. PubMed ID: 16313801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of Bone Marrow Mesenchymal Stem Cells in Resistance of Chronic Myeloid Leukemia to Tyrosine Kinase Inhibitors -Review].
    Zhang XY; Wan Q; Fang LJ; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1901-1904. PubMed ID: 28024517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.
    Jootar S; Pornprasertsud N; Petvises S; Rerkamnuaychoke B; Disthabanchong S; Pakakasama S; Ungkanont A; Hongeng S
    Leuk Res; 2006 Dec; 30(12):1493-8. PubMed ID: 16839603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells.
    Xu Y; Ikeda S; Sumida K; Yamamoto R; Tanaka H; Minato N
    Nat Commun; 2018 Mar; 9(1):914. PubMed ID: 29500416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Wang J; Hu J; Jin Z; Wan H
    Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of cellular and immune-related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes.
    Jafarzadeh N; Safari Z; Pornour M; Amirizadeh N; Forouzandeh Moghadam M; Sadeghizadeh M
    J Cell Physiol; 2019 Apr; 234(4):3697-3710. PubMed ID: 30317554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
    Diaz-Blanco E; Bruns I; Neumann F; Fischer JC; Graef T; Rosskopf M; Brors B; Pechtel S; Bork S; Koch A; Baer A; Rohr UP; Kobbe G; von Haeseler A; Gattermann N; Haas R; Kronenwett R
    Leukemia; 2007 Mar; 21(3):494-504. PubMed ID: 17252012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells.
    Charaf L; Mahon FX; Lamrissi-Garcia I; Moranvillier I; Beliveau F; Cardinaud B; Dabernat S; de Verneuil H; Moreau-Gaudry F; Bedel A
    Leukemia; 2017 Jan; 31(1):65-74. PubMed ID: 27220663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
    Zuo S; Sun L; Wang Y; Chen B; Wang J; Ge X; Lu Y; Yang N; Shen P
    Cell Death Dis; 2021 Feb; 12(2):208. PubMed ID: 33627636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia.
    Oviedo A; Yañez R; Colmenero I; Aldea M; Rubio A; Bueren JA; Lamana ML
    Cell Transplant; 2013; 22(8):1381-94. PubMed ID: 23044223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia stem cells.
    Jamieson CH
    Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
    Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
    Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of BCR/ABL Translocation in Bone Marrow Derived Mesenchymal Stem Cells in Egyptian CML Patients.
    Gaafar TM; Raafat II; Aly AA; Mohamed NA; Farid RJ; Saad NE; El-Hawary R; Mostafaa N; Ahmed MM
    Open Access Maced J Med Sci; 2015 Jun; 3(2):231-6. PubMed ID: 27275226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.